SHARE:
FacebookTwitterFacebookPrintShare

Comparative Effectiveness of Therapies for Clinically Localized Prostate Cancer

Systematic Review ARCHIVED Feb 5, 2008

Related Files

Archived: This report has been updated.

People using assistive technology may not be able to fully access information in these files. For additional assistance, please contact us.

Excerpt

This report summarizes evidence comparing the relative effectiveness and safety of treatment options for clinically localized prostate cancer. The report addresses the following questions: 1) What are the comparative risks, benefits, short- and long-term outcomes of therapies for clinically localized prostate cancer? 2) How do specific patient characteristics, e.g., age, race/ethnicity, presence or absence of comorbid illness, preferences (e.g., tradeoff of treatment-related adverse effects vs. potential for disease progression), affect the outcomes of these therapies, overall and differentially? 3) How do provider/hospital characteristics affect outcomes overall and differentially (e.g., geographic region and volume)? 4) How do tumor characteristics, e.g., Gleason score, tumor volume, screen vs. clinically detected tumors, affect the outcomes of these therapies, overall and differentially?

Project Timeline

Comparative Effectiveness of Therapies for Clinically Localized Prostate Cancer

Jan 1, 2005
Topic Initiated
Feb 5, 2008
Systematic Review Archived
Page last reviewed December 2019
Page originally created November 2017

Internet Citation: Systematic Review: Comparative Effectiveness of Therapies for Clinically Localized Prostate Cancer. Content last reviewed December 2019. Effective Health Care Program, Agency for Healthcare Research and Quality, Rockville, MD.
https://effectivehealthcare.ahrq.gov/products/prostate-cancer/research

Select to copy citation